FutureChem’s FC705: A Game-Changer in Prostate Cancer Treatment

FutureChem Acquires US Patent for Prostate Cancer Treatment “FC705” FutureChem acquired a patent for prostate cancer treatment in the United States after Europe and China. FutureChem announced on the 7th that FC705, a radiopharmaceutical targeting cell membrane antigen (PSMA) for the diagnosis and treatment of prostate cancer, has obtained a patent registration in the United […]
The post FutureChem’s FC705: A Game-Changer in Prostate Cancer Treatment appeared first on News Directory 3.